Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An international conference - Ketamine and Related Compounds for Psychiatric Disorders - will take place on 6-8 April 2020, in Oxford.

Hufton & Crow

The conference is open to clinical and non-clinical academic or industry people with an interest in ketamine and related compounds for psychiatry disorders.

Attending the conference is a great opportunity to hear about new clinical and pre-clinical data on this new class of controversial drugs and how they might be used, alone or with psychotherapy.

Associate Professor, Rupert McShane will host the three-day conference, which includes an excellent cast of international speakers, such as:

  • Carlos Zarate, NIMH, Chief, Experimental Therapeutics & Pathophysiology Branch

  • Jerry Sanacora, Director of Yale Depression Program
  • Celia Morgan, Professor of Psychopharmacology, Exeter University

  • Paul Glue, Hazel Buckland Professor; Division of Health Sciences Associate Dean (Research Commercialisation); Dunedin University, NZ

 

I am delighted to be welcoming so many of the world's leading researchers to our conference in Oxford. We are at a pivotal moment when decisions in the UK are being made about the use of ketamine and related drugs for resistant depression. This is the perfect time to discuss and find out more about glutamatergic drugs and how they may affect psychiatric practice. Associate Professor Rupert McShane, Department of Psychiatry, University of Oxford.

 

There are two options for participation, either attending the conference in person or as an online participant.

Online 'e-delegates' will have access to all the talks, which are live-streamed, as well as an opportunity to participate in scheduled web-meetings which will discuss e-presentations (a novel, interactive alternative to posters). 

Delegates (either attending in person or online) can submit material for discussion in an e-presentation, once registered. These e-presentations can include studies of ketamine or closely related compounds, descriptions of content and timing of adjunctive psychotherapy, descriptions of dosing schedules, opinion about deployment, discussions of practical interest to clinicians and policy discussions. E-presentation materials will be available to review from 27 March.

 

Please contact rupert.mcshane@oxfordhealth.nhs.uk to discuss.

On the first evening of the conference (6 April) the Lancet Psychiatry is hosting a debate - this house believe that there is sufficient evidence for the wide prescription of ketamine for resistant depression, at Convocation House, the seat of parliament during the English Civil War.

Costs:

Attendance in person = £295 (academic/NHS)

Online e-delegate = £25

Venue:

Blavatnik School of Government
University of Oxford
Radcliffe Observatory Quarter
Woodstock Road
Oxford OX2 6GG

The conference is supported by the NIHR Oxford Health Biomedical Research Centre.

For more information or to register.

 

 

 

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.